AlzeCure Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer’s

AlzeCure Pharma AB announced that a new scientific article has been published on the Phase I clinical results supporting the continued development of the lead candidate drug NeuroRestore ACD856.